Monograph Details
|
|
Central Nervous System
> Parkinsonism
|
|
ELDEPRYL |
| Manufacturer |
|
Somerset Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
MAOI, type B. |
| Generic Name |
|
Selegiline HCl 5mg; caps. |
| Indications |
|
Adjunct to levodopa/ carbidopa in Parkinsonism. |
| Children |
|
Not recommended. |
| Adults |
|
5mg at breakfast and at lunch; max 10mg/day. After 2–3 days, levodopa/ carbidopa dosage may be reduced by 10–30%; further reductions may be possible later. |
| Contraindications |
|
Concomitant meperidine, other opioids (See Interactions). |
| Precautions |
|
Selectivity for MAO type B diminishes at doses over 10mg/day. Pregnancy (Cat.C). Nursing mothers: not recommended. |
| Interactions |
|
Contraindicated with meperidine, possibly other opioids (hyperpyretic crisis). Avoid concomitant tricyclic antidepressants or selective serotonin reuptake inhibitors (SSRIs). Allow at least 5 weeks (or more if used chronically or at high doses) between fluoxetine discontinuance and 2 weeks between paroxetine or sertraline discontinuance before starting selegiline; allow 2 weeks between selegiline discontinuance before starting tricyclic antidepressants or SSRIs. Caution with tyramine-containing foods and with sympathomimetics. |
| Adverse Reactions |
|
Nausea, dizziness, lightheadedness, syncope, abdominal pain, confusion, vivid dreams, hallucinations, dry mouth, headache. |
| How Supplied |
|
Caps—60 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
